The board of directors of Consun Pharmaceutical Group Limited announced that Ms. LI Qian (Ms. Li) has resigned from the position of the chief executive officer, with effect from 17 January 2024, due to health reasons. The Company announces that Mr. An Meng, the Chairman of the Board and an executive Director, has been appointed as the chief executive officer with effect from 17 January 2024. Pursuant to code provision C.2.1 of the Corporate Governance Code in Appendix 14 to the Rules Governing the Listing of Securities on the Stock Exchange, the roles of chairman and the chief executive officer should be separate and should not be performed by the same individual.

Despite the deviation from C.2.1 of the code provision of the Listing Rules for Mr. An Meng serves as the Chairman of the Board as well as the chief executive officer of the Company, the Board believes that Mr. An Meng being the Chairman of the Board, is familiar with the Company's business operation and has excellent knowledge and experience of the Company's business which will be conducive to improving the efficiency of the Company's overall strategic planning.